Elevation Oncology

Elevation Oncology is a leading biotechnology company dedicated to discovering and developing innovative, selective cancer therapies. Focused on addressing significant unmet medical needs across a range of solid tumors, Elevation Oncology is committed to rethinking drug development by matching innovative therapies to the unique characteristics of a patient's tumor. Their lead candidate, EO-3021, is a potential best-in-class antibody drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target.

Elevation Oncology's EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Located at 101 Federal St, Suite 1900, Boston, Massachusetts 02110, US, Elevation Oncology is working to rapidly advance EO-3021 into clinical trials in the US across a range of solid tumor indications. The company is also actively exploring new opportunities through partnerships and business development to further expand its novel oncology pipeline.

Elevation Oncology is dedicated to transforming cancer treatment and improving patient outcomes. We invite the management team at Elevation Oncology to create a customized and exclusive company showcase and product listing on our platform, and thank you for your work to make a difference in Biotechnology.